LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 11 of 15: Mean cell count and mean normalized growth rate inhibition values across biological replicate 1. - Dataset (ID:20248)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Mitoxantrone | 10 | uM | LJP6 | 72 | hr | 1476 | 544 | 3643 | 0.1497 | -0.5368 |
| MCF7 | AZD 5438 | 10 | uM | LJP6 | 72 | hr | 1235 | 381 | 4056 | 0.0939 | -0.4975 |
| MCF7 | CGP60474 | 10 | uM | LJP6 | 72 | hr | 1235 | 383 | 4056 | 0.0945 | -0.4947 |
| SK-BR-3 | Geldanamycin | 10 | uM | LJP5 | 72 | hr | 1476 | 597 | 3772 | 0.1583 | -0.4897 |
| MCF7 | Mitoxantrone | 10 | uM | LJP6 | 72 | hr | 1235 | 408 | 4056 | 0.1006 | -0.4766 |
| BT-20 | LDN-193189 | 10 | uM | LJP5 | 72 | hr | 1657 | 545 | 5588 | 0.0977 | -0.4702 |
| SK-BR-3 | Mitoxantrone | 10 | uM | LJP5 | 72 | hr | 1476 | 630 | 3772 | 0.1671 | -0.4674 |
| SK-BR-3 | QL-XII-47 | 10 | uM | LJP6 | 72 | hr | 1476 | 659 | 3643 | 0.1810 | -0.4631 |
| MCF7 | Canertinib | 10 | uM | LJP6 | 72 | hr | 1235 | 430 | 4056 | 0.1061 | -0.4595 |
| MCF7 | Mitoxantrone | 10 | uM | LJP5 | 72 | hr | 1235 | 420 | 4267 | 0.0987 | -0.4544 |
| SK-BR-3 | LDN-193189 | 10 | uM | LJP5 | 72 | hr | 1476 | 662 | 3772 | 0.1758 | -0.4476 |
| SK-BR-3 | Geldanamycin | 10 | uM | LJP6 | 72 | hr | 1476 | 688 | 3643 | 0.1889 | -0.4449 |
| BT-20 | A443654 | 10 | uM | LJP6 | 72 | hr | 1657 | 652 | 5383 | 0.1212 | -0.4241 |
| SK-BR-3 | CGP60474 | 10 | uM | LJP6 | 72 | hr | 1476 | 732 | 3643 | 0.2016 | -0.4177 |
| MDA-MB-231 | Mitoxantrone | 10 | uM | LJP6 | 72 | hr | 868 | 290 | 3556 | 0.0816 | -0.4170 |
| BT-20 | CGP60474 | 10 | uM | LJP6 | 72 | hr | 1657 | 673 | 5383 | 0.1252 | -0.4116 |
| MCF7 | Alvocidib | 10 | uM | LJP6 | 72 | hr | 1235 | 512 | 4056 | 0.1258 | -0.4073 |
| MCF7 | CGP60474 | 3.33 | uM | LJP6 | 72 | hr | 1235 | 514 | 4056 | 0.1269 | -0.4009 |
| SK-BR-3 | Omipalisib | 10 | uM | LJP6 | 72 | hr | 1476 | 765 | 3643 | 0.2101 | -0.3979 |
| SK-BR-3 | GSK1059615 | 10 | uM | LJP5 | 72 | hr | 1476 | 757 | 3772 | 0.2010 | -0.3905 |
| MDA-MB-231 | Mitoxantrone | 10 | uM | LJP5 | 72 | hr | 868 | 331 | 3410 | 0.0969 | -0.3874 |
| MDA-MB-231 | LDN-193189 | 10 | uM | LJP5 | 72 | hr | 868 | 332 | 3410 | 0.0973 | -0.3860 |
| SK-BR-3 | AT-7519 | 10 | uM | LJP6 | 72 | hr | 1476 | 788 | 3643 | 0.2184 | -0.3826 |
| MCF7 | Alvocidib | 3.33 | uM | LJP6 | 72 | hr | 1235 | 542 | 4056 | 0.1338 | -0.3813 |
| MCF7 | Geldanamycin | 10 | uM | LJP5 | 72 | hr | 1235 | 525 | 4267 | 0.1234 | -0.3802 |